Peter A. LeWitt, MD, directs the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital in West Bloomfield, Michigan and is professor of neurology at Wayne State University School of Medicine. In addition to extensive experience in conducting clinical trials for Parkinson’s disease and other neurological disorders, his research interests have included pre-clinical models and biomarkers of neurological disease, pharmacokinetic analysis of neurological drugs, and gene therapy. He is the author of more than 300 publications in basic and clinical neuroscience.

Dr. LeWitt attended Brown University and its medical school, and completed his postgraduate medical training at the University of Pennsylvania and Stanford University School of Medicine. He is Board-certified in neurology. At the National Institute of Neurological Disorders and Stroke (National Institutes of Health), he served as a research fellow in the Experimental Therapeutics Branch and had an appointment as lieutenant commander in the U.S. Public Health Service.

Dr. LeWitt was a founding member of the Parkinson Study Group and in 1998 was elected to serve as secretary of the Movement Disorder Society (now the International Parkinson and Movement Disorder Society), for which he serves as a member of that organization’s Task Force for the Development of Rating Scales for Parkinson’s Disease. Dr. LeWitt has received research grants from the National Institutes of Health, The Michael J. Fox Foundation for Parkinson’s Research, The Harris Foundation Neuroscience Program, the National Parkinson Foundation and other organizations. Since 2003, he has been editor-in-chief of Clinical Neuropharmacology and has served on the editorial boards of Movement Disorders, Journal of Neural Transmission, Journal of Parkinson’s Disease and Translational Neurodegeneration.

Dr. LeWitt has been the mentor for several movement disorder fellowship trainees and has been active in educational programs conducted by the Movement Disorder Society, the American Academy of Neurology, the European Federation of Neurological Sciences and other organizations. He has served as a clinical trial and neuropharmacology consultant in the development of therapies for neurological disorders.